Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
20/20 BiolabsAIDX -0.23%6 FCF Margin % is -366.57% as of Mar. 2026. GuruFocus rates AIDX with a GF Score™ of 6/100. The stock has 1 warning sign investors should review. Among 816 Medical Devices & Instruments companies, 20/20 Biolabs ranks worse than 88.6% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. 20/20 Biolabs's Free Cash Flow for the
three
months ended in Mar. 2026 was $-1.29 Mil. 20/20 Biolabs's Revenue for the
three
months ended in Mar. 2026 was $0.35 Mil. Therefore, 20/20 Biolabs's FCF Margin % for the quarter that ended in Mar. 2026 was -366.57%.
The historical data trend for 20/20 Biolabs's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, 20/20 Biolabs's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
20/20 Biolabs FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, 20/20 Biolabs's FCF Margin % distribution charts can be found below:
* The bar in red indicates where 20/20 Biolabs's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
20/20 Biolabs (AIDX) has a FCF Margin % of -366.57% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 20/20 Biolabs and its competitors. According to the industry distribution chart, 20/20 Biolabs ranks #723 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 88.6%.
Is 20/20 Biolabs' FCF Margin % too high?
20/20 Biolabs' current FCF Margin % is -366.57%. Based on the distribution chart, 20/20 Biolabs ranks #723 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, 20/20 Biolabs has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does 20/20 Biolabs' FCF Margin % compare to STME and TRIB?
According to the Medical Devices & Instruments industry distribution chart, 20/20 Biolabs ranks #723 out of 816 companies for FCF Margin %. This places 20/20 Biolabs in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on 20/20 Biolabs and its competitors. 20/20 Biolabs's current FCF Margin % is -366.57%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 20/20 Biolabs stock overvalued right now?
20/20 Biolabs (AIDX) has a current FCF Margin % of -366.57%. The current FCF Margin % is -366.57%. 20/20 Biolabs' overall GF Score™ is 6/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For 20/20 Biolabs (AIDX), the current FCF Margin % is -366.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
6GF Score
Get the complete analysis for AIDX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AIDX has been successfully added to your 
